Parataxis to Acquire Bridge Biotherapeutics for $18.3M, Launch Korea’s First Bitcoin Treasury
Parataxis Holdings LLC has agreed to invest $18.3 million (KRW 25 billion) to acquire a controlling stake in South Korea’s Bridge Biotherapeutics. Upon closing, the biotech firm will be rebranded as Parataxis Korea and pivot its corporate focus to Bitcoin treasury management. Leveraging Parataxis Capital’s digital asset expertise, the new entity will integrate Bitcoin into its balance sheet and adopt a Bitcoin treasury strategy. The board will be reshaped with blockchain specialists and a new CEO experienced in crypto treasury. Inspired by MicroStrategy’s success and amid growing corporate crypto adoption—public companies now hold over 777,000 BTC—this move marks a milestone for South Korea’s regulated market. Recent pilot programs for verified crypto accounts and proposed spot Bitcoin ETF laws further signal broader industry acceptance.
Bullish
This move signals strong institutional demand for Bitcoin treasury strategies. By establishing the first publicly traded Bitcoin treasury platform in South Korea, Parataxis demonstrates confidence in long-term corporate crypto adoption. Such milestones typically boost market sentiment and can drive BTC price appreciation as traders anticipate increased institutional inflows and regulatory acceptance.